TW202346282A - Shp2抑制劑之結晶鹽形式 - Google Patents

Shp2抑制劑之結晶鹽形式 Download PDF

Info

Publication number
TW202346282A
TW202346282A TW112110698A TW112110698A TW202346282A TW 202346282 A TW202346282 A TW 202346282A TW 112110698 A TW112110698 A TW 112110698A TW 112110698 A TW112110698 A TW 112110698A TW 202346282 A TW202346282 A TW 202346282A
Authority
TW
Taiwan
Prior art keywords
cancer
compound
ppm
following
additional therapeutic
Prior art date
Application number
TW112110698A
Other languages
English (en)
Chinese (zh)
Inventor
凱蒂 基頓 布朗
康納 詹姆士 卡卓瑞
亞倫 祺思 古德溫
Original Assignee
美商亞雷生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商亞雷生物製藥股份有限公司 filed Critical 美商亞雷生物製藥股份有限公司
Publication of TW202346282A publication Critical patent/TW202346282A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW112110698A 2022-03-23 2023-03-22 Shp2抑制劑之結晶鹽形式 TW202346282A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23
US63/323,005 2022-03-23

Publications (1)

Publication Number Publication Date
TW202346282A true TW202346282A (zh) 2023-12-01

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112110698A TW202346282A (zh) 2022-03-23 2023-03-22 Shp2抑制劑之結晶鹽形式

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2025509818A (ja) 2025-04-11
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
AR128847A1 (es) 2024-06-19
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
KR20240163705A (ko) 2024-11-19
AU2023238523B2 (en) 2025-10-30
AU2023238523A1 (en) 2024-08-22
MX2024011603A (es) 2024-09-30
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
CN113480542B (zh) 化合物的固体形式和制剂
TW202519524A (zh) 固態形式
ES2402524T5 (es) Sal de malato de la N-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida y formas cristalinas de la misma para el tratamiento del cáncer
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
TW202430184A (zh) Kras g12d抑制劑的結晶形式及製備方法
TW201704237A (zh) 適用於治療與ｋｉｔ及ｐｄｆｇｒ相關之病症的組合物
KR20120051702A (ko) Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
EP3878852A1 (en) Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
KR20230165309A (ko) Shp2 억제제의 결정질 형태
WO2017016463A1 (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
TWI889708B (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
JP2023536892A (ja) Ｊａｋ阻害剤化合物及びその使用
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
US9120815B2 (en) Solid state forms of macrocyclic kinase inhibitors
US20250214966A1 (en) Crystalline Salt Form Of A SHP2 Inhibitor
CN114026088A (zh) Jak2抑制剂的结晶形式
AU2020242723A1 (en) BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
HK40112682A (zh) Shp2抑制剂的结晶盐形式
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
EP4570800A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
CA3263285A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof
HK40101911A (zh) Shp2抑制剂的晶型
EP4367116A1 (en) Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof